Volume 95, Issue 4 pp. 291-297
Research Article

Non-inflammatory skin involvement in breast cancer, histologically proven but without the clinical and histological T4 category features

Uwe Gueth MD

Corresponding Author

Uwe Gueth MD

Department of Gynecology and Obstetrics, University Hospital Basel (UHB), Spitalstrasse, Basel, Switzerland

Department of Gynecology and Obstetrics, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland. Fax: 0041-61-2659037.Search for more papers by this author
Edward Wight MD

Edward Wight MD

Department of Gynecology and Obstetrics, University Hospital Basel (UHB), Spitalstrasse, Basel, Switzerland

Search for more papers by this author
Andreas Schoetzau MS

Andreas Schoetzau MS

JPS Institute for Biomathematics, Malzgasse, Basel, Switzerland

Search for more papers by this author
Igor Langer MD

Igor Langer MD

Department of Surgery, UHB, Spitalstrasse, Basel, Switzerland

Search for more papers by this author
Holger Dieterich MD

Holger Dieterich MD

Women's Hospital and Breast Center Rheinfelden, Therese-Herzog-Weg, Rheinfelden, Germany

Search for more papers by this author
Christoph Rochlitz MD

Christoph Rochlitz MD

Department of Medical Oncology, UHB, Petersgraben, Basel, Switzerland

Search for more papers by this author
Linda Herberich MD

Linda Herberich MD

Department of Gynecology and Obstetrics, University Hospital Basel (UHB), Spitalstrasse, Basel, Switzerland

Search for more papers by this author
Wolfgang Holzgreve MD

Wolfgang Holzgreve MD

Department of Gynecology and Obstetrics, University Hospital Basel (UHB), Spitalstrasse, Basel, Switzerland

Search for more papers by this author
Gad Singer MD

Gad Singer MD

University of Basel, Institute of Pathology, Schönbeinstrasse, Basel, Switzerland

Search for more papers by this author
First published: 26 February 2007
Citations: 10

Abstract

Background

The study evaluates characteristics and prognostic significance of breast cancer with histologically proven non-inflammatory skin involvement but without the clinical and histological features that are mandatory for inclusion in the T4 category.

Methods

We compared retrospectively the clinical course of 55 patients with this clinico-pathologic entity to the outcome of a control group of 309 consecutive patients with tumors of the same size but without skin involvement. The median follow-up time was 6.6 years in the study and 8.4 years in the control group. Two subsets were analyzed: (A) 1.1–2.0 cm (T1c); (B) 2.1–5.0 cm (T2).

Results

The distribution of TNM stages within Study Group A was: Stage I: 28.6%, Stage II: 61.9%, Stage III: 9.5%. The distribution within Study Group B was: Stage II: 67.7%, Stage III: 23.5%, and Stage IV: 8.8%. Differences in disease-specific survival (DSS) between study and control groups were not significant. In multivariate analysis, skin involvement was not a significant variable, while lymph node involvement was found to be significant for worse outcome (Group A: HR = 3.99 [1.33–12.05], P = 0.014; Group B: HR = 2.37 [1.37–4.08], P = 0.002).

Conclusion

Breast carcinomas with histologically proven skin involvement without the clinical and histological correlate are a heterogeneous group of cases, but the majority of the patients have Stage I/II disease. While lymph node involvement had a most significant effect on DSS, skin involvement was not a significant prognostic factor. Physicians must be aware of this clinico-pathologic entity in order not to misclassify these cases as T4 and consider them falsely as being locally advanced breast cancer. J. Surg. Oncol. 2007;95:291–297. © 2007 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.